Document is current
Any future updates will be listed below
-
Authors
Legido-Quigley, Cristina https://orcid.org/0000-0002-4018-214X
Wewer Albrechtsen, Nicolai J. https://orcid.org/0000-0003-4230-5753
Bæk Blond, Martin
Corrales Compagnucci, Marcelo
Ernst, Madeleine
Herrgård, Markus J. https://orcid.org/0000-0003-2377-9929
Minssen, Timo https://orcid.org/0000-0002-3286-4888
Ottosson, Filip https://orcid.org/0000-0002-8312-3545
Pociot, Flemming
Rossing, Peter https://orcid.org/0000-0002-1531-4294
Sulek, Karolina https://orcid.org/0000-0002-7117-3756
-
Funding
Funding for this research was provided by:
Novo Nordisk Fonden (NNF0074491, NNF23SA0087056, NNF23SA0087056)
Lundbeckfonden
EC | Horizon 2020 Framework Programme (101057321)
- License Information
-
More Information
Article History
First Online: 17 January 2025
Competing interests
: C.L.Q. received consultancy fees from Pfizer; honoraria, travel or speakers’ fees from Biogen; and research funds from Pfizer and Novo Nordisk and is the director of the company BrainLogia. N.J.W.A. has received research support, personal support and speaker fees from EvoSep, Mercodia, Novo Nordisk, Merck, MSD and Boehringer Ingelheim. F.P. received advisory, speaking and lecture fees from Sanofi Aventis. P.R. received consultancy and/or speaking fees (to his institution) from Abbott, AstraZeneca, Bayer, Boehringer Ingelheim, Daichii Sankyo, Eli Lilly, Gilead, Novo Nordisk and Sanofi, as well as research grants from AstraZeneca Bayer and Novo Nordisk. T.M. served as a consultant to Corti, Microsoft, The European Union and the World Health Organization. The current paper was initiated and written when K.S. was employed at Steno Diabetes Center Copenhagen. During the review process and the final submission, K.S. changed affiliation to Novo Nordisk. The other authors declare no competing interests.
